June 17, 2025
2 min watch
CHICAGO — On this video, Susana M. Campos, MD, MPH, discusses outcomes from the ROSELLA section 3 examine of relacorilant plus nab-paclitaxel in sufferers with platinum-resistant ovarian most cancers.
Relacorilant (Corcept Therapeutics), an investigational selective glucocorticoid receptor antagonist, together with nab-paclitaxel demonstrated PFS and OS profit in contrast with nab-paclitaxel monotherapy, in accordance with outcomes offered at ASCO Annual Assembly.
“The median progression-free survival within the examine group was about 6.5 months vs. the taxane group, which was about 5.52 months,” Campos, scientific director of the division of gynecologic oncology at Dana-Farber Most cancers Institute and assistant professor of drugs at Harvard Medical College, stated. “It’s a clinically modest enchancment, however regardless of this modest enchancment, the general survival did favor the mixture of the glucocorticoid antagonist plus the taxane.”
Reference:
Olawaiye A, et al. Summary LBA5507. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
